Quick Answer
Alaunos Therapeutics, Inc. reported Total Revenue of $5.0 thousand for fiscal year 2025.
Alaunos Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $5.0K -50.0% |
$10.0K +100.0% |
$5.0K -99.8% |
$2.92M +634.2% |
$398.0K | $0.00 |
| Revenue (ASC 606) | $5.0K -50.0% |
$10.0K +100.0% |
$5.0K -99.8% |
$2.92M +634.2% |
$398.0K | $0.00 |
| Net Income | -$4.18M +10.8% |
-$4.68M +0.0% |
-$4.68M +87.6% |
-$37.73M +52.1% |
-$78.75M +1.5% |
-$79.98M +32.1% |
| Diluted EPS | -$2.20 +24.7% |
-$2.92 +86.7% |
-$21.97 -741.8% |
-$2.61 -605.4% |
-$0.37 +2.6% |
-$0.38 +45.7% |
| Total Assets | $2.97M +7.7% |
$2.75M -66.7% |
$8.26M -87.3% |
$64.94M -31.5% |
$94.86M -35.2% |
$146.34M +34.1% |
| Cash and Equivalents | $1.39M +26.9% |
$1.09M -82.0% |
$6.06M -84.5% |
$39.06M -48.6% |
$76.05M -33.9% |
$115.07M +44.3% |
| Long-Term Debt | — | — | — | $0.00 -100.0% |
$16.25M | $0.00 |
| Stockholders Equity | $2.15M +4.4% |
$2.06M -67.3% |
$6.31M -83.6% |
$38.55M -33.6% |
$58.06M -53.2% |
$123.98M +30.5% |
| R&D Expense | $1.36M +276.5% |
$362.0K -97.8% |
$16.28M -34.9% |
$25.02M -49.6% |
$49.64M -5.8% |
$52.70M +37.5% |
| Operating Income | -$4.22M +12.2% |
-$4.81M +86.0% |
-$34.27M +2.4% |
-$35.10M +54.7% |
-$77.55M +3.5% |
-$80.36M -38.9% |
| Shares Outstanding | 2.35M +46.7% |
1.60M +0.0% |
1.60M -90.0% |
16.03M -92.6% |
216.13M +0.7% |
214.59M +18.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$1.16M | -2.8% | -10.3% |
| Diluted EPS | September 30, 2025 | -$0.55 | +21.4% | +12.7% |
| Total Assets | September 30, 2025 | $3.72M | +4.9% | -21.4% |
| Cash and Equivalents | September 30, 2025 | $1.94M | +15.2% | -32.7% |
| Long-Term Debt | September 30, 2022 | $0.00 | -100.0% | -100.0% |
| Stockholders Equity | September 30, 2025 | $2.80M | +2.9% | -23.4% |
| R&D Expense | September 30, 2025 | $469.0K | +228.0% | +153.5% |
| Operating Income | September 30, 2025 | -$1.19M | -3.2% | -14.2% |
| Shares Outstanding | September 30, 2025 | 2.21M | +37.8% | +6.3% |
- Alaunos Therapeutics, Inc. reported Total Revenue of $5.0 thousand for fiscal year 2025.
- Alaunos Therapeutics, Inc. showed a decrease of -50.0% in Total Revenue compared to the prior fiscal year.
- Alaunos Therapeutics, Inc. reported Revenue (ASC 606) of $5.0 thousand for fiscal year 2025.
- Alaunos Therapeutics, Inc. showed a decrease of -50.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Alaunos Therapeutics, Inc. reported Net Income of -$4.18 million for fiscal year 2025.
- Alaunos Therapeutics, Inc. showed an increase of +10.8% in Net Income compared to the prior fiscal year.
- Alaunos Therapeutics, Inc. reported Diluted EPS of $2.20 per share (loss) for fiscal year 2025.
- Alaunos Therapeutics, Inc. showed an increase of +24.7% in Diluted EPS compared to the prior fiscal year.
- Alaunos Therapeutics, Inc. reported Total Assets of $2.97 million for fiscal year 2025.
- Alaunos Therapeutics, Inc. showed an increase of +7.7% in Total Assets compared to the prior fiscal year.
- Alaunos Therapeutics, Inc. reported Cash and Equivalents of $1.39 million for fiscal year 2025.
- Alaunos Therapeutics, Inc. showed an increase of +26.9% in Cash and Equivalents compared to the prior fiscal year.
- Alaunos Therapeutics, Inc. reported Long-Term Debt of $0.00 for fiscal year 2022.
- Alaunos Therapeutics, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Alaunos Therapeutics, Inc. reported Stockholders Equity of $2.15 million for fiscal year 2025.
- Alaunos Therapeutics, Inc. showed an increase of +4.4% in Stockholders Equity compared to the prior fiscal year.
- Alaunos Therapeutics, Inc. reported R&D Expense of $1.36 million for fiscal year 2025.
- Alaunos Therapeutics, Inc. showed an increase of +276.5% in R&D Expense compared to the prior fiscal year.
- Alaunos Therapeutics, Inc. reported Operating Income of -$4.22 million for fiscal year 2025.
- Alaunos Therapeutics, Inc. showed an increase of +12.2% in Operating Income compared to the prior fiscal year.
- Alaunos Therapeutics, Inc. reported Shares Outstanding of 2.35 million shares for fiscal year 2025.
- Alaunos Therapeutics, Inc. showed an increase of +46.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: